Fig. 3

66-year-old patient presented with grade 3 IDC TNBC planned to receive AC (adriamycin and cyclophosphamide) 4 cycles and 12 cycles of taxol. a–d SWE baseline, post-first, second, and fourth cycles, respectively. The stiffness ratio in the lesion, their change, and percent change were post-first cycle 9.6, − 57.4, and − 85.6%, respectively. Post-second cycle, the stiffness ratio, change in stiffness ratio, and percent change were 3.9, − 63.1, and − 94%, and post-fourth cycle the stiffness ratio, change in stiffness ratio, and percent change were 8.4, − 58, and − 87%. Postoperative pathology revealed pCR